A gene therapy for geographic atrophy, a complication of age-related macular degeneration, has been granted fast-track status from the US Food and Drug Administration.
Sanofi, who are developing the therapy, is preparing a Phase 1/2 clinical trial to test the one-shot gene therapy.
Pharmaphorum has more details.